Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in atherosclerosis prevention

Current Cardiology Reports

Volumn 14, Issue 4, 2012, Pages 433-442

  Aponte, Maria M Patarroyo ^a   Francis, Gary S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Atherosclerosis; Prevention; Renin angiotensinaldosterone system

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FLUINDOSTATIN; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; METOPROLOL; NIFEDIPINE; OLMESARTAN; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; RENIN INHIBITOR; SIMVASTATIN; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; MICROALBUMINURIA; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84865575056     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0275-9     Document Type: Article

References (66)

1. Lonn E. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Curr Atheroscler Rep. 2002;4 (5):363-72.
2. •• Ferrario C. Effect of angiotensin receptor blockade on endothelial function: Focus on olmesartan medoxomil. Vasc Health Risk Manag. 2009;5(1):301-14. This is a complete review regarding effects of ARBs on atherosclerosis prevention. It also gives a great explanation of the pathophysiology of RAAS and atherosclerosis.
3. • Vijayaraghavan K, Deedwania P. Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention. Cardiol Clin. 2011;29(1):137-56. This article gives a complete explanation of the role of RAAS in atherosclerosis.
4. Virmani R, Robinowitz M, Geer JC, et al. Coronary artery atherosclerosis revisited in Korean war combat casualties. Arch Pathol Lab Med. 1987;111(10):972-6. (Pubitemid 17145651)
5. •• Shahin Y, Khan JA, Samuel N, Chetter I. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: A meta-analysis of randomized controlled trials. Atherosclerosis. 2011;216(1):7-16. This meta-analysis shows the effect of ACEIs on endothelial dysfunction, which is the first step for atherosclerosis.
6. Dzau VJ. Tissue angiotensin and pathobiology of vascular diseasea unifying hypothesis. Hypertension. 2001;37(4):1047-52. (Pubitemid 32304002)
7. Dzau VJ, Bernstein K, Celermejer D, et al. The relevance of tissue angiotensin-converting enzyme; manifestations in mechanistic and endpoint dat. Am J Cardiol. 2001;88(9A):1L-20L. (Pubitemid 33022712)
8. McDonald KM, Mock J, D'Aloia A, et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation. 1995;91(7):2043-8.
9. Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996;94(11):2756-67. (Pubitemid 26411739)
10. Wassmann S, Czech T, van Eickels M, et al. Inhibition of diet induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double knockout mice. Circulation. 2004;110(19):3062-7. (Pubitemid 39491999)
11. • Fukuda D, Enomoto S, Nagai R, Sata M. Inhibition of reninangiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. Biomed pharmacother. 2009;63(10):754-61. This article demonstrate the effect of RAAS in vascular infiltration by macrophages and the possibility that inhibition of RAAS will lead to not just prevention but reduction of atherosclerotic lesion.
12. Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet induced hypercholesterolemia. Circulation. 2000;101(13):1586-93. (Pubitemid 30180896)
13. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15 suppl 5:S65-72. (Pubitemid 20159139)
14. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15(3):327-31. (Pubitemid 20097461)
15. Hoshida S, Nishida M, Yamashita N, et al. Vascular angiotensinconverting enzyme prevent myointimal proliferation after vascular injury. Atherosclerosis. 1997;130(1-2):53-9.
16. Rolland PH, Carpiot P, Friggi A, et al. Effects of angiotensinconverting enzyme inhibition with perindopril on hemodynamics, arterial structure and wall rheology in the hindquarters of atherosclerosis mini-pigs. Am J Cardiol. 1993;71(17):22E-7E. (Pubitemid 23179568)
17. Powell JS, Clozel JP, Müller RK, et al. Inhibitors of angiotensinconverting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245(4914):186-8. (Pubitemid 19193936)
18. Yusuf S, Sleight P, Pogue J, Bosch J, et al. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342(3):145-53.
19. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomized, double blind, placebo controlled, multicenter trial (the EUROPA study). Lancet. 2003;362(9386):782-8. (Pubitemid 37093919)
20. PROGRESS collaborative group. Randomized trial of a perindoprilbased blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet. 2001;358 (9287):1033-41.
21. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood pressure lowering arm (ASCOT-BPLA) a multicentre randomized controlled trial. Lancet. 2005;366(9489):895-906. (Pubitemid 41265663)
22. Ahimastos AA, Lawler A, Reid CM, et al. Brief communication: Ramipril markedly improves walking ability in patients with peripheral arterial disease: A randomized trial. Ann Intern Med. 2006;144(9):660-4. (Pubitemid 46780650)
23. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensinconverting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058- 68.
24. Nakamura M, Funakoshi T, Arakawa N, et al. Effect of angiotensin- converting enzyme inhibitors on endotheliumdependent peripheral vasodilation in patients with chronic heart failure. J Am Coll Cardiol. 1994;24(5):1321-7. (Pubitemid 24331873)
25. Millgárd J, Hägg A, Sarabi M, Lind L. Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients. J Hum Hypertens. 1998;12(8):511-6. (Pubitemid 28430219)
26. Mühlen BV, Millgård J, Lind L. Effects of digoxin, furosemide, enalaprilat and metoprolol on endothelial function in young normotensive subjects. Clin Exp Pharmacol Physiol. 2001;28(5-6):381-5. (Pubitemid 32538903)
27. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (trial on Reversing Endothelial Dysfunction) study. Circulation. 1996;94(3):258-65. (Pubitemid 26266107)
28. Kovacs I, Toth J, Tarjan J, Koller A. Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE. Eur J Heart fail. 2006;8(5):451-9.
29. Hermann TS, Li W, Dominguez H, et al. Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J CLin End Metab. 2006;91(3):1001-8. (Pubitemid 43357772)
30. Girerd X, Giannattasio C, Moulin C, et al. Regression of radial artery wall hypertrhophy and improvement of carotid artery compliance after long term antihypertensive treatment in elderly patients. J Am Coll Cardiol. 1998;31(5):1064-73. (Pubitemid 28212507)
31. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressureindependent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006;48(1):80-6. (Pubitemid 44313590)
32. Joannides R, Bizet-Nafeh C, Costentin A, et al. Chronic ACE inhibitors enhances the endothelial control of arterial mechanisms and flow-dependent vasodilatation in heart failure. Hypertension. 2001;38(6):1446-50. (Pubitemid 34033431)
33. Yavuz D, Kov M, Toprak A, et al. Effects of ACE inhibition and AT-1 receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin Angiotensin Aldosterone syst. 2003;4(3):197-203. (Pubitemid 37407169)
34. Watanabe S, Tagawa T, Yamakawa K, et al. Inhibition of the reninangiotensin system prevents free fatty acid induced acute endothelial dysfunction in humans. Arterioscler thromb Vasc Biol. 2005;25(11):2376-80. (Pubitemid 41552657)
35. Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensinconverting enzyme inhibition increases human vascular tissue type plasminogen activator release through endogenous bradykinin. Circulation. 2003;107(4):579-85. (Pubitemid 36176808)
36. Mullens MJ, Clarkson P, Donald AE, et al. Effect of enalapril on endothelial function in young insulin dependent diabetic patients: A randomized double blind study. J Am Coll Cardiol. 1998;31 (6):1330-5. (Pubitemid 28219124)
37. Cashin-Hemphill L, Holmvang G, Chan RC, et al. Angiotensin converting enzyme inhibition as anti-atherosclerotic therapy: An answer yet. Quinapril ischemic event trial. Am J Cardiol. 1999;83(1):43-7.
38. Bots ML, Remme WJ, Lüscher TF, EUROPA-PERFECT Investigators, et al. ACE inhibition and endothelial function: Main findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc, Drug Ther. 2007;21(4):269-79. (Pubitemid 47387473)
39. Ceconi C, Fox KM, RemmeWJ, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007;73(1):237-46. (Pubitemid 44937193)
40. Fleming I, Kohlstedt K, Busse R. The Tissue renin-angiotensin system and intracellular signaling. Curr Opin Nephrol Hypertens. 2006;15:8-13.
41. Lazar HL, Bao Y, Rivers S, Colton T, Bernard SA. High tissue affinity angiotensin-converting enzyme inhibitors improve endothelial function and reduce infarct size. Ann Thorac Surg. 2001;72 (2):548-53. (Pubitemid 32727168)
42. Ruzicka M, Coletta E, White R, et al. Effects of ACE inhibitors on cardiac angiotensin II and aldosterone in humans: "Relevance of lipophilicity and affinity for ACE". Am J Hypertens. 2010;23 (11):1179-82.
43. Jorde UP, Vittorio TJ, DImayuga CA, et al. Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure. Am J Cardiol. 2004;94(12):1501-5. (Pubitemid 40268450)
44. Yusuf S, Teo KK, Pogue J, et al. ONTARGET investigators: Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59. (Pubitemid 351522739)
45. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med. 2003;349 (20):1893-906. (Pubitemid 37409706)
46. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE study group: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet. 2002;359(9311):995-1003. (Pubitemid 34286536)
47. Rizzoni D, Porteri E, De Ciuceis C, et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension. 2005;45(4):659-65. (Pubitemid 40418362)
48. Koh KK, Quon MJ, Lee Y, et al. Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. Eur Heart J. 2007;28(12):1440-7. (Pubitemid 47343820)
49. Schmieder RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes care. 2007;30(6):1351-6. (Pubitemid 46871137)
50. Koh KK, Quon MJ, Han SH, et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol. 2010;140(1):73-81.
51. • Toyama K, Nakamura T, Kataoka K, et al. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferation activated receptor-γ-dependent activity. Biochem Biophys Res Commun. 2011;410(3):508-13. This article showed an additional effect of RAAS inhibition in diabetes mellitus patients beyond the renal protection.
52. Pellicia F, Pasceri V, Cianfrocca C, et al. Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: A randomized, double-blind, placebo controlled study. Atherosclerosis. 2010;210(2):510-5.
53. • Zankl AR, Ivandic B, Andrassy M, et al. Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease. Clin Res Cardiol. 2010;99(12):787-94. This randomized, placebo-controlled, double-blind trial showed improvement in symptoms in peripheral vascular disease, with a greater magnitude than the one reported by other therapies.
54. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by angiotensin receptor antagonist losartan. Circulation. 2000;101(14):1653-9. (Pubitemid 30196624)
55. Olsen MH, Watchell K, Neland K, et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood press. 2005;14(3):177-83. (Pubitemid 41015717)
56. Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65(3):1041-9. (Pubitemid 38251080)
57. Fliser D, Buchholz K, Haller H. European trial on Olmesartan and pravastatin in inflammation and atherosclerosis (EUTOPIA) investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110(9):1103-7. (Pubitemid 39319009)
58. Hackam DG, Sultan NM, Criqui MH. Vascular protection in peripheral artery disease: Systematic review and modeling study. Heart. 2009;95(13):1098-102.
59. •• Koh KK, Han SH, Oh PC, et al. Combination therapy for treatment or prevention of atherosclerosis: Focus on the lipid-RAAS interaction. Atherosclerosis. 2010;209(2):307-13. The article provides useful information and explanation of possible effects of combination therapy in atherosclerosis prevention.
60. Li Z, Iwai M, Wu L, et al. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension. 2004;44(5):758-63. (Pubitemid 39435250)
61. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004;110 (24):3687-92. (Pubitemid 39665258)
62. Koh KK, Quon MJ, Han SH, et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension. 2005;45(6):1088-93. (Pubitemid 40770310)
63. Koh KK, Quon MJ, Han SH, et al. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. Atherosclerosis. 2007;194(1):230-7. (Pubitemid 47464302)
64. Ceriello A, Assaloni R, Da Ros R, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress and inflammation in type 2 diabetic patients. Circulation. 2005;111(19):2518-24. (Pubitemid 40696141)
65. Messerli FH, Yuzefpolskaya M. Q: Is an ACE inhibitor plus an ARB more effective than either drug alone? Cleve Clin J Med. 2009;76(12):693-6.
66. Messerli FH. The sudden demise of dual renin-angiotensin system blockade of the soft science of the surrogate end point. J Am Coll Cardiol. 2009;53(6):468-70.